Last reviewed · How we verify
VE303
VE303 is a live biotherapeutic product that modulates the gut microbiome to treat inflammatory bowel disease.
VE303 is a live biotherapeutic product that modulates the gut microbiome to treat inflammatory bowel disease. Used for Moderate to severe ulcerative colitis.
At a glance
| Generic name | VE303 |
|---|---|
| Sponsor | Vedanta Biosciences, Inc. |
| Drug class | live biotherapeutic product |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
VE303 works by introducing a combination of live microbes into the gut to restore a balanced microbiome, which helps to reduce inflammation and promote healing in the gastrointestinal tract.
Approved indications
- Moderate to severe ulcerative colitis
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
Key clinical trials
- VE303 for Prevention of Recurrent Clostridioides Difficile Infection (PHASE3)
- VE303 for Treatment of Hepatic Encephalopathy (HE) (PHASE2)
- Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection (PHASE2)
- First-in-human Study of VE303 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VE303 CI brief — competitive landscape report
- VE303 updates RSS · CI watch RSS
- Vedanta Biosciences, Inc. portfolio CI